Compare VRTX & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | BMY |
|---|---|---|
| Founded | 1989 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.6B | 127.0B |
| IPO Year | 2007 | 2006 |
| Metric | VRTX | BMY |
|---|---|---|
| Price | $517.10 | $59.02 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 32 | 28 |
| Target Price | ★ $595.36 | $65.25 |
| AVG Volume (30 Days) | 1.3M | ★ 9.0M |
| Earning Date | 11-02-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 4.32% |
| EPS Growth | ★ 836.54 | 178.46 |
| EPS | ★ 10.90 | 3.98 |
| Revenue | $2,488,652,000.00 | ★ $48,194,000,000.00 |
| Revenue This Year | $10.46 | $4.23 |
| Revenue Next Year | $10.53 | N/A |
| P/E Ratio | $47.77 | ★ $14.66 |
| Revenue Growth | ★ 46.20 | N/A |
| 52 Week Low | $412.27 | $47.58 |
| 52 Week High | $568.67 | $68.64 |
| Indicator | VRTX | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 39.40 |
| Support Level | $493.75 | $55.66 |
| Resistance Level | $536.58 | $60.93 |
| Average True Range (ATR) | 15.90 | 1.71 |
| MACD | -3.73 | -0.46 |
| Stochastic Oscillator | 4.74 | 13.93 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.